William Blair, Sofi
Denali Therapeutics’ (DNLI) Outperform Rating Reiterated at William Blair
William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report published on Wednesday,RTT News reports. Other equities research analysts also recently issued research reports about the company.
William Blair has upgraded CVRx (NASDAQ:CVRX) to outperform from market perform, citing utilization improvements and ...
For investors looking for opportunities in fintech, SoFi presents an interesting case. Here's where analysts think the stock ...
Equities researchers at William Blair raised their FY2024 EPS estimates for shares of Moderna in a research report issued to ...
On Friday, Federal Signal Corp (FSS) stock saw a decline, ending the day at $97.2 which represents a decrease of $-0.64 or -0.65% from the prior close of $97.84. The stock opened at $99.37 and touched ...
William Blair analyst Dylan Becker has maintained their bullish stance on KARO stock, giving a Buy rating on January 13.Stay Ahead of the ...
CHICAGO, January 07, 2025--(BUSINESS WIRE)--William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, has named Stewart ...
Stock Trading Recap. On Friday, Tenaya Therapeutics Inc (TNYA) stock saw a modest uptick, ending the day at $1.4 which represents a slight increase ...
Equities research analysts at William Blair cut their Q4 2025 earnings per share estimates for shares of Karooooo in a report ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback